Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease.
BACKGROUND
The safety and efficacy of second-line chemotherapy for treating patients with small cell lung cancer (SCLC) and interstitial lung disease (ILD) have not been elucidated to date.


METHODS
Between January 2005 and September 2013, we analyzed 23 patients with SCLC and ILD who received second-line chemotherapy. Pre-existing ILD was diagnosed according to clinical features and pretreatment chest high-resolution computed tomography results.


RESULTS
The overall objective response rates and disease control rates were 22% and 52%, respectively. The median respective durations of progression-free survival and overall survival were 2.1 months (95% confidence interval (CI)=2.0-3.0 months) and 7.1 months (95% CI=3.6-11.3 months), respectively. Three patients with unusual interstitial pneumonia pattern (13%) developed chemotherapy-related pneumonitis.


CONCLUSIONS
Second-line treatment may be an effective and safe option for SCLC patients with ILD after sufficient evaluation of risks and benefits.
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan daichianzen@yahoo.co.jp.
Daichi
D
Fujimoto
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Ryoko
R
Shimizu
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Ryoji
R
Kato
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Yuki
Y
Sato
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Mariko
M
Kogo
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Jiro
J
Ito
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Shunsuke
S
Teraoka
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Takehiro
T
Otoshi
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Kazuma
K
Nagata
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Atsushi
A
Nakagawa
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Kojiro
K
Otsuka
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Nobuyuki
N
Katakami
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Keisuke
K
Tomii
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D016879:Salvage Therapy; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D019772:Topotecan / Q000008:administration & dosage
D019772:Topotecan; D016190:Carboplatin; D017239:Paclitaxel
Chemotherapy-related exacerbation; interstitial lung disease; small cell lung cancer; usual interstitial pneumonia